Cerevel Therapeutics Holdings, Inc. CERE
We take great care to ensure that the data presented and summarized in this overview for Cerevel Therapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CERE
View all-
Bain Capital Investors LLC Boston, MA65.7MShares$2.68 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$440 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$308 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$304 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$222 Million0.01% of portfolio
-
State Street Corp Boston, MA3.53MShares$144 Million0.01% of portfolio
-
Fil LTD Hamilton, D03.25MShares$132 Million0.14% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.34MShares$95.4 Million3.86% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.33MShares$94.9 Million3.7% of portfolio
-
Pentwater Capital Management LP Naples, FL2.22MShares$90.4 Million0.98% of portfolio
Latest Institutional Activity in CERE
Top Purchases
Top Sells
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at CERE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 10
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
50,000
-76.18%
|
$2,100,000
$42.1 P/Share
|
May 10
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+43.24%
|
$150,000
$3.5 P/Share
|
Apr 01
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
50,000
-76.18%
|
$2,100,000
$42.33 P/Share
|
Apr 01
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+43.24%
|
$150,000
$3.5 P/Share
|
Mar 04
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
50,000
-76.18%
|
$2,050,000
$41.01 P/Share
|
Mar 04
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+43.24%
|
$150,000
$3.5 P/Share
|
Feb 29
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
50,000
-76.18%
|
$2,050,000
$41.16 P/Share
|
Feb 29
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+43.24%
|
$150,000
$3.5 P/Share
|
Feb 20
2024
|
Perceptive Advisors LLC Director |
SELL
Bona fide gift
|
Indirect |
170,317
-100.0%
|
-
|
Feb 07
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
2,506
-13.81%
|
$102,746
$41.54 P/Share
|
Feb 07
2024
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,161
-25.33%
|
$88,601
$41.54 P/Share
|
Feb 06
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
15,440
+45.97%
|
-
|
Feb 06
2024
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,020
+37.05%
|
-
|
Jan 02
2024
|
N Anthony Coles |
SELL
Open market or private sale
|
Direct |
50,000
-94.87%
|
$2,100,000
$42.24 P/Share
|
Jan 02
2024
|
N Anthony Coles |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+48.68%
|
$150,000
$3.5 P/Share
|
Dec 26
2023
|
Ramiro Sanchez Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-40.53%
|
$420,000
$42.47 P/Share
|
Dec 26
2023
|
Ramiro Sanchez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+28.84%
|
$30,000
$3.5 P/Share
|
Dec 26
2023
|
Kathleen Tregoning |
BUY
Exercise of conversion of derivative security
|
Direct |
3,150
+22.8%
|
$31,500
$10.05 P/Share
|
Dec 22
2023
|
Kenneth Di Pietro Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
8,000
-24.49%
|
$328,000
$41.45 P/Share
|
Dec 22
2023
|
Kenneth Di Pietro Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+19.67%
|
$24,000
$3.5 P/Share
|
Last 12 Months Summary
Open market or private purchase | 17.4M shares |
---|---|
Exercise of conversion of derivative security | 907K shares |
Grant, award, or other acquisition | 26.3K shares |
Bona fide gift | 170K shares |
---|---|
Open market or private sale | 839K shares |
Other acquisition or disposition | 1.3M shares |